Similar articles

Abstract: Objective: This study was performed to evaluate whether implantation of mesenchymal stem cell (MSC) would reduce left ventricular remodelling from the molecular mechanisms compared with angiotensin-converting enzyme inhibitors (ACEIs) perindopril into ischemic myocardium after acute myocardial infarction. Methods: Forty rats were divided into four groups: control, MSC, ACEI, MSC+ACEI groups. Bone marrow stem cell derived rat was injected immediately into a zone made ischemic by coronary artery ligation in MSC group and MSC+ACEI group. Phosphate-buffered saline (PBS) was injected into control group. perindopril was administered p.o. to ACEI group and MSC+ACEI group. Six weeks after implantation, the rats were killed and heart sample was collected. Fibrillar collagen was observed by meliorative Masson’s trichome stain. Western Blotting was employed to evaluate the protein expression of matrix metalloproteinase (MMP)-2, matrix metalloproteinase (MMP)-9 in infarction zone. The transcriptional level of MMP2, MMP9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in infarction area was detected by reverse transcriptase PCR (RT-PCR) analysis. Results: The fibrillar collagen area, the protein expression of MMP2, MMP9 and the transcriptional level of MMP2, MMP9 mRNA in infarction zone reduced in MSC group, ACEI group, and MSC+ACEI group. No significant difference was detected in the expression of TIMP1 mRNA among the 4 groups. Conclusion: Both MSC and ACEI could reduce infarction remodelling by altering collagen metabolism.

[1] Chen, S.L., Fang, W.W., Ye, F., Liu, Y.H., Qian, J., Shan, S.J., Zhang, J.J., Chunhua, R.Z., Liao, L.M., Lin, S., Sun, J.P., 2004. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol., 94(1):92-95.

[2] Fedak, P.W., Szmitko, P.E., Weisel, R.D., Altamentova, S.M., Nili, N., Ohno, N., Verma, S., Fazel, S., Strauss, B.H., Li, R.K., 2005. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. Virchows Arch., 14:1-11.

[3] Garcia, R.A., Brown, K.L., Pavelec, R.S., Go, K.V., Covell, J.W., Villarreal, F.J., 2005. Abnormal cardiac wall motion and early matrix metalloproteinase activity. Am. J. Physiol. Heart Circ. Physiol., 288(3):H1080-H1087.

[4] Ikonomidis, J.S., Hendrick, J.W., Parkhurst, A.M., Herron, A.R., Escobar, P.G., Dowdy, K.B., Stroud, R.E., Hapke, E., Zile, M.R., Spinale, F.G., 2005. Accelerated LV remodelling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am. J. Physiol. Heart Circ. Physiol., 288(1):H149-H158.

[5] Møller, J.E., Dahlstrom, U., Gotzsche, O., Lahiri, A., Skagen, K., Andersen, G.S., Egstrup, K., 2004. OPTIMAAL study group effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the optimal trial in myocardial infarction with angiotensin II antagonist losartan (OPTIMAAL) echocardiographic substudy. Am. Heart J., 147(3):494-501.

[6] Mujumdar, V.S., Tyagi, S.C., 1999. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J. Hypertens, 17:261-270.

[7] Papadopoulos, D.P., Economou, E.V., Makris, T.K., Kapetanios, K.J., Moyssakis, I., Votteas, V.E., Toutouzas, P.K., 2004. Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. Drugs Exp. Clin. Res., 30(2):55-65.

[8] Papadopoulos, D.P., Moyssakis, I., Makris, T.K., Poulakou, M., Stavroulakis, G., Perrea, D., Votteas, V.E., 2005. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction. Eur. Cytokine Netw., 16(2):152-160.

[9] Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Dougls, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., Marshak, D.R., 1999. Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411):143-147.

[10] Porter, K.E., Turner, N.A., O'Regan, D.J., Ball, S.G., 2004. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc. Res., 64(3):507-515.

[11] Reinhardt, D., Sigusch, H.H., Hensse, J., Tyagi, S.C., Korfer, R., Figulla, H.R., 2002. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart, 88(5):525-530.

[12] Roten, L., Nemoto, S., Simsic, J., Coker, M.L., Rao, V., Baicu, S., Defreyte, G., Soloway, P.J., Zile, M.R., Spinalefl, F.G., 2000. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol., 32(1):109-120.

[13] Spinale, F.G., 2002. Matrix metalloproteinases regulation and dysregulation in the failing heart. Circ. Res., 90(5):520-530.

[14] Strauer, B.E., Brehm, M., Zeus, T., Gattermann, N., Hernandez, A., Sorg, R.V., Kogler, G., Wernet, P., 2001. Intracoronary, human autologus stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch. Med. Wochenschr., 126(34-35):932-938 (in German).

[15] Xie, Z., Singh, M., Singh, K., 2004. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1 beta. J. Biol. Chem., 279(38):39513-39519.

[16] Xu, X., Xu, Z., Xu, Y., Cui, G., 2005. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron. Artery Dis., 16(4):245-255.

[17] Yang, L.X., Zhu, S.J., Yang, Y.J., Guo, C.M., Qi, F., Wei, L., Shi, Y.K., Wang, Y., Ren, L., 2004. Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodelling. Chinese Journal of Internal Medicine, 43(11):828-831 (in Chinese).